Innovent Biologics
Innovent Biologics, also known as Innovent, is a leading biopharmaceutical company headquartered in China (CN). Founded in 2011, the company has rapidly established itself in the biopharmaceutical industry, focusing on the development, manufacturing, and commercialisation of innovative therapies for oncology, autoimmune diseases, and other serious conditions. With a strong presence in major operational regions across Asia and beyond, Innovent is recognised for its robust pipeline of monoclonal antibodies and biosimilars. Their flagship products, including the PD-1 inhibitor Tyvyt, have garnered significant attention for their unique mechanisms of action and efficacy. Innovent's commitment to research and development has positioned it as a key player in the global market, achieving notable milestones such as successful partnerships and regulatory approvals that underscore its reputation for excellence in biopharmaceutical innovation.
DitchCarbon Score
How does Innovent Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innovent Biologics's score of 40 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Innovent Biologics's reported carbon emissions
In 2024, Innovent Biologics reported total carbon emissions of approximately 14,115,290 kg CO2e, with Scope 1 emissions at about 47,780 kg CO2e and Scope 2 emissions at approximately 14,067,510 kg CO2e. This represents a significant decrease from 2023, where total emissions were about 15,894,420 kg CO2e, comprising Scope 1 emissions of approximately 65,170 kg CO2e and Scope 2 emissions of about 15,829,250 kg CO2e. In 2022, the company recorded total emissions of approximately 22,302,950 kg CO2e, with Scope 1 emissions at about 66,740 kg CO2e and Scope 2 emissions at approximately 22,236,210 kg CO2e. The trend indicates a reduction in emissions over the years, particularly from 2022 to 2024. Despite these reductions, Innovent Biologics has not set specific reduction targets or initiatives, nor does it have any climate pledges documented. The emissions data is not cascaded from a parent company, and all figures are reported directly from Innovent Biologics, Inc. Overall, Innovent Biologics is making strides in reducing its carbon footprint, particularly in Scope 2 emissions, while continuing to monitor and report its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 60,540 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 15,934,330 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Innovent Biologics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
